IXICO Final Earnings Report

IXICO EPS Results

• Actual EPS: -GBX 4.14
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

IXICO Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

IXICO Announcement Details

• Quarter: Final
• Date: 12/4/2024
• Time: Before Market Opens

IXICO (LON:IXI) is a fast growing and profitable medical data analytics company, providing data management and advanced analytics to the pharmaceutical clinical trials market. Established in 2004 and listed as a public company in October 2013, IXICO has firmly established itself as a trusted partner to the global pharmaceutical industry developing new therapies for neurological conditions such as Alzheimer’s, Parkinson’s and Huntington’s disease. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience. We will focus on developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients. Our integrated technology offering encompasses every stage of clinical drug development through to post marketing surveillance and we continue to invest in infrastructure and innovation to support our ambitious growth strategy. Our competitive advantage is our dedication to address complex unmet clinical research needs by partnering and collaborating with clients and academic partners early in the drug development cycle to identify and validate promising new imaging and digital biomarkers.